Data Sharing and Reproducibility
- Milestone 3.A •
Provide resources to make datasets from existing and legacy clinical research studies on AD and related dementias widely accessible…
- Milestone 3.B •
Provide support to establish/improve the interoperability among relevant biomedical data repositories.…
- Milestone 3.C •
Increase transparency in reporting and reproducibility of research findings by incentivizing and enforcing rapid sharing…
- Milestone 3.D •
Enable access to data and associated biosamples and biomarkers from completed, ongoing and future, federally and privately funded clinical trials...
- Milestone 3.E •
Accelerate independent evaluation of research findings by mandating the open distribution of publicly and privately/philanthropically funded computational and experimental research tools...
- Milestone 3.F •
Democratize the use of large scale molecular and clinical data by building computational infrastructure for sustainable data storage...
- Milestone 3.G •
Develop data and resource infrastructures to support management and collaborative analysis of diverse resources from FTD basic science and clinical studies.
- Milestone 3.H •
Improve rigor, reproducibility, and translatability of discovery research.
Portfolio Analysis Tools and Methods
Public Private Partnerships
- Milestone 14.A •
Convene an advisory meeting focused on facilitating public-private partnerships aimed at accelerating the development and test of effective therapies for AD treatment and prevention...
- Milestone 14.B •
Convene meetings of the working groups for (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation...
- Milestone 14.C •
Develop partnerships to support novel/disruptive science that would incentivize students and early-career investigators to adopt a collaborative approach...
- Milestone 14.D •
Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning...
- Milestone 14.E •
Develop a partnership among key stakeholders to implement the sharing of all data and biosamples from preclinical and clinical studies ...
- Milestone 14.F •
Update consensus on AD/ADRD nomenclature necessary to identify target populations for intervention research...
- Milestone 14.G •
Convene an advisory meeting of relevant stakeholders to develop a consensus regarding eliminating barriers to sharing, integrating, and reuse of data...
- Milestone 14.H •
Alter institutional practices that impede team science and data sharing in academia
- Milestone 14.I •
Develop and disseminate best practices for the collection, processing, and multi-omics molecular profiling of human and animal model biosamples.
- Milestone 14.J •
Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector...
Translational Tools, Infrastructure, and Capabilities
- Milestone 4.A •
Support the development of the next generation of animal models based on the current understanding of genetic and environmental risk and protective factors for AD and related dementias…
- Milestone 4.B •
Create infrastructure/resources for extensive characterization of existing and new animal models…
- Milestone 4.C •
Continue to develop animal models with higher predictive validity for use in preclinical drug development…
- Milestone 4.D •
Expand biorepository infrastructure to enable storage and rapid distribution of clinical data and biosamples…
- Milestone 4.E •
Support the development of standardized, cost-effective, high throughput methods…
- Milestone 4.F •
Develop improved iPSC protocols for all relevant cell types and human-based organoid model systems...
- Milestone 4.G •
Support quantitative systems pharmacology approaches that couple biological network and pathway analyses…
- Milestone 4.H •
Institute an expedited review track for applications focused on drug discovery, preclinical, and clinical drug development...
- Milestone 4.I •
Create a National IRB.
- Milestone 4.J •
Expand existing and create new integrative training programs for junior neuroscience, behavioral and social science researchers...
- Milestone 4.K •
Leverage the power of human genetics to enable precision medicine research for AD...
- Milestone 4.L •
Support standardized, single cell molecular profiling (genomic, proteomic, metabolomic)...
- Milestone 4.M •
Support the development of genome-scale metabolic models to capture the heterogeneity of metabolic transitions...
- Milestone 4.N •
Provide support for high-cost capital equipment/core facilities and staff training to make high-throughput technologies...
- Milestone 4.O •
De-risk novel candidate targets by supporting the development of high quality, open source, target enabling tools...
- Milestone 4.W •
Enable open drug development to generate innovative new medicines that are priced fairly for all.
- Milestone 4.X •
Create opportunities and avenues for closer interaction between researchers developing new INDs and researchers supported through NIA's enabling infrastructure programs involved in developing data
- Milestone 4.Y •
Evaluate and update current trial funding models to ensure the ability to test novel first-in-class therapeutics in the context of the full range of expenses and time frames required for robust
AD Related Dementias - Specific
- Milestone 4.P •
Create an international FTD clinical trial network.
- Milestone 4.Q •
Develop better FTLD in vivo and cell-based model systems.
- Milestone 4.R •
Develop models that: reproduce small vessel disease; are relevant to VCID and AD; address white and grey matter VCID; or include genetic and acquired VCID. Verify models, including via imaging.
- Milestone 4.S •
Improve and increase training, including for individuals who are members of under-represented populations, and of different career levels of scholars who conduct health disparities research in AD/ADRD
- Milestone 4.T •
Use data and other resources from large-scale clinical research and trials to test hypothesized mechanisms of human VCID in basic science models.
- Milestone 4.U •
Incorporate VCID findings from basic science into the design of clinical research and trials targeting VCID-relevant cognitive impairment and dementia.
- Milestone 4.V •
Build new animal models to advance knowledge about TDP-43 pathology in common dementias, capitalizing on lessons learned from animal models in FTLD/ALS, AD and other diseases.
- Milestone 14.K •
Establish effective communication between NIH and NGOs
- Milestone 14.L •
Organize a working group of stakeholders, including health disparities communities, to develop more consistent nomenclature in dementia research and care.
- Milestone 14.M •
Generate an AD/ADRD health disparities task force